CA3072960A1 - Stabilized nucleic acids encoding messenger ribonucleic acid (mrna) - Google Patents
Stabilized nucleic acids encoding messenger ribonucleic acid (mrna) Download PDFInfo
- Publication number
- CA3072960A1 CA3072960A1 CA3072960A CA3072960A CA3072960A1 CA 3072960 A1 CA3072960 A1 CA 3072960A1 CA 3072960 A CA3072960 A CA 3072960A CA 3072960 A CA3072960 A CA 3072960A CA 3072960 A1 CA3072960 A1 CA 3072960A1
- Authority
- CA
- Canada
- Prior art keywords
- adenine
- nucleotides
- poly
- dna
- consecutive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004999 messenger RNA Proteins 0.000 title claims description 9
- 108020004707 nucleic acids Proteins 0.000 title description 3
- 102000039446 nucleic acids Human genes 0.000 title description 3
- 150000007523 nucleic acids Chemical class 0.000 title description 3
- 229920002477 rna polymer Polymers 0.000 title description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims abstract description 503
- 239000002773 nucleotide Substances 0.000 claims abstract description 96
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 84
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 61
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 61
- 108020004414 DNA Proteins 0.000 claims description 126
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 74
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 63
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 61
- 108091033409 CRISPR Proteins 0.000 claims description 47
- 229930024421 Adenine Natural products 0.000 claims description 29
- 229960000643 adenine Drugs 0.000 claims description 29
- 239000013598 vector Substances 0.000 claims description 29
- 229940113082 thymine Drugs 0.000 claims description 27
- 229920001519 homopolymer Polymers 0.000 claims description 24
- 229940104302 cytosine Drugs 0.000 claims description 22
- 102000028499 poly(A) binding Human genes 0.000 claims description 19
- 108091023021 poly(A) binding Proteins 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 230000004543 DNA replication Effects 0.000 claims description 11
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 4
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 229940035893 uracil Drugs 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 description 65
- 150000003838 adenosines Chemical class 0.000 description 44
- 102100022662 Guanylyl cyclase C Human genes 0.000 description 30
- 101710198293 Guanylyl cyclase C Proteins 0.000 description 30
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 28
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 27
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 22
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 13
- 102100029812 Protein S100-A12 Human genes 0.000 description 13
- 101710110949 Protein S100-A12 Proteins 0.000 description 13
- 229960005305 adenosine Drugs 0.000 description 13
- 108020005004 Guide RNA Proteins 0.000 description 11
- 238000000137 annealing Methods 0.000 description 11
- 230000008685 targeting Effects 0.000 description 11
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 10
- 101150062912 cct3 gene Proteins 0.000 description 10
- 108010071690 Prealbumin Proteins 0.000 description 9
- 102000009190 Transthyretin Human genes 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 7
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 5
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001788 irregular Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 4
- 108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 4
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 4
- 101710102163 Atrial natriuretic peptide receptor 1 Proteins 0.000 description 4
- 241001123946 Gaga Species 0.000 description 4
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 4
- 102100032442 Protein S100-A8 Human genes 0.000 description 4
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229940021993 prophylactic vaccine Drugs 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 3
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 3
- 101100154776 Mus musculus Ttr gene Proteins 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 2
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 2
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 101000963424 Homo sapiens Acetyl-CoA carboxylase 1 Proteins 0.000 description 2
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 2
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 2
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 2
- 241000342334 Human metapneumovirus Species 0.000 description 2
- 241000712003 Human respirovirus 3 Species 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102100035304 Lymphotactin Human genes 0.000 description 2
- 108091060294 Messenger RNP Proteins 0.000 description 2
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 2
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 2
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 235000001046 cacaotero Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 238000013492 plasmid preparation Methods 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- JEOQACOXAOEPLX-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1CSCN1.OC(=O)[C@@H](N)CCCN=C(N)N JEOQACOXAOEPLX-WCCKRBBISA-N 0.000 description 1
- 108010052418 (N-(2-((4-((2-((4-(9-acridinylamino)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)amino)-1-(1H-imidazol-4-ylmethyl)-1-oxoethyl)-6-(((-2-aminoethyl)amino)methyl)-2-pyridinecarboxamidato) iron(1+) Proteins 0.000 description 1
- JGSQPOVKUOMQGQ-VPCXQMTMSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-methoxyoxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1=CC(=O)NC(=O)N1[C@]1(OC)O[C@H](CO)[C@@H](O)[C@H]1O JGSQPOVKUOMQGQ-VPCXQMTMSA-N 0.000 description 1
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 1
- BCOSEZGCLGPUSL-UHFFFAOYSA-N 2,3,3-trichloroprop-2-enoyl chloride Chemical compound ClC(Cl)=C(Cl)C(Cl)=O BCOSEZGCLGPUSL-UHFFFAOYSA-N 0.000 description 1
- GHCVXTFBVDVFGE-UHFFFAOYSA-N 4-amino-6-chloro-1,3,5-triazin-2-ol Chemical compound NC1=NC(O)=NC(Cl)=N1 GHCVXTFBVDVFGE-UHFFFAOYSA-N 0.000 description 1
- SVDVJBWDBYSQLO-UHFFFAOYSA-N 5-(4-hydroxy-3-methoxyphenyl)-5-phenylimidazolidine-2,4-dione Chemical compound C1=C(O)C(OC)=CC(C2(C(NC(=O)N2)=O)C=2C=CC=CC=2)=C1 SVDVJBWDBYSQLO-UHFFFAOYSA-N 0.000 description 1
- QJIUMVUZDYPQRT-UHFFFAOYSA-N 6-chloro-2,4-pyrimidinediamine Chemical compound NC1=CC(Cl)=NC(N)=N1 QJIUMVUZDYPQRT-UHFFFAOYSA-N 0.000 description 1
- 102100039239 Amidophosphoribosyltransferase Human genes 0.000 description 1
- 241001351283 Arta Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 102100024246 Caspase activity and apoptosis inhibitor 1 Human genes 0.000 description 1
- 101710196418 Caspase activity and apoptosis inhibitor 1 Proteins 0.000 description 1
- 201000009182 Chikungunya Diseases 0.000 description 1
- 102100034330 Chromaffin granule amine transporter Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000641221 Homo sapiens Chromaffin granule amine transporter Proteins 0.000 description 1
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 1
- 101000937642 Homo sapiens Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 1
- 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102100027329 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000772176 Mus musculus Transthyretin Proteins 0.000 description 1
- 101100109406 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aga-1 gene Proteins 0.000 description 1
- WSDRAZIPGVLSNP-UHFFFAOYSA-N O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O Chemical compound O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O WSDRAZIPGVLSNP-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101000690429 Panax ginseng Floral homeotic protein AGAMOUS Proteins 0.000 description 1
- 102000019200 Poly(A)-Binding Protein I Human genes 0.000 description 1
- 108010012887 Poly(A)-Binding Protein I Proteins 0.000 description 1
- 101710150485 Polyadenylate-binding protein Proteins 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 1
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 description 1
- 101001009851 Rattus norvegicus Guanylate cyclase 2G Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 101150071661 SLC25A20 gene Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101150091380 TTR gene Proteins 0.000 description 1
- 201000008754 Tenosynovial giant cell tumor Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000020329 Zika virus infectious disease Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 1
- -1 adenosine monophosphates Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 101150102633 cact gene Proteins 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035647 diffuse type tenosynovial giant cell tumor Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- CJWXCNXHAIFFMH-AVZHFPDBSA-N n-[(2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,5-dihydroxy-6-methyloxan-4-yl]acetamide Chemical compound C[C@H]1O[C@@H](O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)[C@H](O)[C@@H](NC(C)=O)[C@@H]1O CJWXCNXHAIFFMH-AVZHFPDBSA-N 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 208000002918 testicular germ cell tumor Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Crystallography & Structural Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545883P | 2017-08-15 | 2017-08-15 | |
| US62/545,883 | 2017-08-15 | ||
| PCT/US2018/046772 WO2019036513A1 (en) | 2017-08-15 | 2018-08-14 | STABILIZED NUCLEIC ACIDS ENCODING MESSENGER RIBONUCLEIC ACID (MRNA) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3072960A1 true CA3072960A1 (en) | 2019-02-21 |
Family
ID=63638316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3072960A Pending CA3072960A1 (en) | 2017-08-15 | 2018-08-14 | Stabilized nucleic acids encoding messenger ribonucleic acid (mrna) |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11673911B2 (enExample) |
| EP (1) | EP3668980A1 (enExample) |
| JP (2) | JP2020532961A (enExample) |
| KR (2) | KR20250004924A (enExample) |
| CN (2) | CN111212908B (enExample) |
| AU (2) | AU2018318135B2 (enExample) |
| BR (1) | BR112020003026A2 (enExample) |
| CA (1) | CA3072960A1 (enExample) |
| CO (1) | CO2020002989A2 (enExample) |
| MX (1) | MX2020001821A (enExample) |
| WO (1) | WO2019036513A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| US12286727B2 (en) | 2016-12-19 | 2025-04-29 | Editas Medicine, Inc. | Assessing nuclease cleavage |
| EP3565907B1 (en) | 2017-01-06 | 2022-05-04 | Editas Medicine, Inc. | Methods of assessing nuclease cleavage |
| EP3615672A1 (en) | 2017-04-28 | 2020-03-04 | Editas Medicine, Inc. | Methods and systems for analyzing guide rna molecules |
| CN110997908A (zh) | 2017-06-09 | 2020-04-10 | 爱迪塔斯医药公司 | 工程化的cas9核酸酶 |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| AU2018318135B2 (en) * | 2017-08-15 | 2024-09-12 | Intellia Therapeutics, Inc. | Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA) |
| KR20250107976A (ko) * | 2017-09-29 | 2025-07-14 | 인텔리아 테라퓨틱스, 인크. | 지질 나노파티클을 이용한 mRNA 전달의 체외 방법 |
| CA3104856A1 (en) | 2018-06-29 | 2020-01-02 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| US20240344019A1 (en) * | 2021-08-17 | 2024-10-17 | Sk Bioscience Co., Ltd. | Method for stably maintaining poly(a) tail |
| WO2023093905A1 (zh) | 2021-11-29 | 2023-06-01 | 上海瑞宏迪医药有限公司 | Aadc、gdnf多核苷酸及其用于治疗帕金森病 |
| WO2023155918A1 (zh) | 2022-02-21 | 2023-08-24 | 上海瑞宏迪医药有限公司 | Vegf结合分子及其医药用途 |
| CN117701602A (zh) * | 2022-08-26 | 2024-03-15 | 深圳瑞吉生物科技有限公司 | 在宿主细胞中稳定存在的多段化PolyA多核苷酸及其应用 |
| CN118581123A (zh) * | 2023-03-01 | 2024-09-03 | 仁景(苏州)生物科技有限公司 | 编码rna的工程化dna分子 |
| CN119799695A (zh) * | 2023-10-10 | 2025-04-11 | 深圳瑞吉生物科技有限公司 | 提高mRNA稳定性以及蛋白表达的多元polyA多核苷酸及其应用 |
| PL446809A1 (pl) * | 2023-11-22 | 2025-05-26 | Sieć Badawcza Łukasiewicz - PORT Polski Ośrodek Rozwoju Technologii | Cząsteczki RNA ze zmodyfikowanymi sekwencjami końca 3' i ich zastosowanie |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| GB202406051D0 (en) | 2024-04-30 | 2024-06-12 | Univ Oxford Innovation Ltd | Segmented poly(a) tails |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08131163A (ja) * | 1994-11-11 | 1996-05-28 | Sankyo Co Ltd | ドメイン変換ヘアピン型リボザイム |
| JP2002360299A (ja) * | 2001-04-20 | 2002-12-17 | Seiwa Technics:Kk | ｍＲＮＡの不安定性を利用したサイトカインの３’非翻訳領域を組み込んだトランスジェニックマウスのガン、炎症などの病変部位検出方法 |
| WO2012019630A1 (en) * | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2013120500A1 (en) * | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| WO2016005004A1 (en) * | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| ES3015369T3 (en) * | 2014-10-09 | 2025-05-05 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid |
| MA41349A (fr) * | 2015-01-14 | 2017-11-21 | Univ Temple | Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn |
| EP3085714B1 (en) * | 2015-04-21 | 2018-03-14 | Rohm And Haas Company | Co2 abating latex coating composition |
| WO2017059902A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| KR101786396B1 (ko) * | 2016-10-27 | 2017-11-24 | 서울대학교산학협력단 | 전령 rna의 3′말단 서열 분석 방법 |
| AU2018318135B2 (en) * | 2017-08-15 | 2024-09-12 | Intellia Therapeutics, Inc. | Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA) |
-
2018
- 2018-08-14 AU AU2018318135A patent/AU2018318135B2/en active Active
- 2018-08-14 CN CN201880066328.XA patent/CN111212908B/zh active Active
- 2018-08-14 MX MX2020001821A patent/MX2020001821A/es unknown
- 2018-08-14 EP EP18772961.1A patent/EP3668980A1/en active Pending
- 2018-08-14 WO PCT/US2018/046772 patent/WO2019036513A1/en not_active Ceased
- 2018-08-14 BR BR112020003026-0A patent/BR112020003026A2/pt unknown
- 2018-08-14 KR KR1020247040420A patent/KR20250004924A/ko active Pending
- 2018-08-14 CA CA3072960A patent/CA3072960A1/en active Pending
- 2018-08-14 JP JP2020508506A patent/JP2020532961A/ja active Pending
- 2018-08-14 CN CN202510029728.5A patent/CN119899831A/zh active Pending
- 2018-08-14 KR KR1020207007211A patent/KR102740888B1/ko active Active
-
2020
- 2020-02-14 US US16/791,076 patent/US11673911B2/en active Active
- 2020-03-13 CO CONC2020/0002989A patent/CO2020002989A2/es unknown
-
2023
- 2023-05-01 US US18/310,298 patent/US12391722B2/en active Active
- 2023-08-25 JP JP2023137160A patent/JP2023179428A/ja active Pending
-
2024
- 2024-12-04 AU AU2024278094A patent/AU2024278094A1/en active Pending
-
2025
- 2025-07-22 US US19/276,658 patent/US20250346625A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020001821A (es) | 2020-09-18 |
| KR102740888B1 (ko) | 2024-12-13 |
| JP2023179428A (ja) | 2023-12-19 |
| US11673911B2 (en) | 2023-06-13 |
| US20200172564A1 (en) | 2020-06-04 |
| CO2020002989A2 (es) | 2020-05-05 |
| JP2020532961A (ja) | 2020-11-19 |
| US20250346625A1 (en) | 2025-11-13 |
| EP3668980A1 (en) | 2020-06-24 |
| US20230271997A1 (en) | 2023-08-31 |
| CN111212908A (zh) | 2020-05-29 |
| US12391722B2 (en) | 2025-08-19 |
| WO2019036513A1 (en) | 2019-02-21 |
| CN111212908B (zh) | 2025-01-24 |
| AU2018318135A1 (en) | 2020-03-05 |
| CN119899831A (zh) | 2025-04-29 |
| BR112020003026A2 (pt) | 2020-08-25 |
| KR20200036025A (ko) | 2020-04-06 |
| KR20250004924A (ko) | 2025-01-08 |
| AU2024278094A1 (en) | 2024-12-19 |
| AU2018318135B2 (en) | 2024-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3072960A1 (en) | Stabilized nucleic acids encoding messenger ribonucleic acid (mrna) | |
| CA3224970A1 (en) | Compositions and methods for efficient genome editing | |
| CN108350454B (zh) | 等位基因选择性基因编辑及其用途 | |
| EP4114940A1 (en) | Methods and compositions for modulating a genome | |
| KR20210148264A (ko) | 중추신경계에서 유전자 발현을 억제하는 조성물 및 방법 | |
| WO2015148860A1 (en) | Crispr/cas-related methods and compositions for treating beta-thalassemia | |
| KR20080031164A (ko) | ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절 | |
| TW201202418A (en) | Treatment of Methionine Sulfoxide Reductase A (MSRA) related diseases by inhibition of natural antisense transcript to MSRA | |
| TW201219569A (en) | Treatment of Sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4 | |
| JPH09504947A (ja) | 標的分子の配列の改変 | |
| US20230114151A1 (en) | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression | |
| CA3122080A1 (en) | Compositions and methods for treating ornithine transcarbamylase deficiency | |
| CN110520532A (zh) | 阻碍硫酸软骨素生物合成的反义核酸 | |
| WO2019044974A1 (ja) | スモールガイドアンチセンス核酸とその使用 | |
| JP2002526072A (ja) | 遺伝子発現の調節のためのヘアピンハイブリダイザー分子 | |
| HK40029231A (en) | Stabilized nucleic acids encoding messenger ribonucleic acid (mrna) | |
| KR20230043819A (ko) | 유전자 전사체의 조정제를 사용한 신경계 질환의 치료 | |
| EP1073731B1 (en) | Nucleic acid enzyme for rna cleavage | |
| JP6021018B2 (ja) | 改良されたオリゴヌクレオチドおよびそのオリゴヌクレオチドを含む医薬組成物 | |
| TW202440921A (zh) | 經修飾之寡核苷酸 | |
| CN117980480A (zh) | 工程化引导rna和多核苷酸 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230803 |